PL2305653T3 - Środek terapeutyczny stosowany w przewlekłej niewydolności nerek - Google Patents

Środek terapeutyczny stosowany w przewlekłej niewydolności nerek

Info

Publication number
PL2305653T3
PL2305653T3 PL09800423T PL09800423T PL2305653T3 PL 2305653 T3 PL2305653 T3 PL 2305653T3 PL 09800423 T PL09800423 T PL 09800423T PL 09800423 T PL09800423 T PL 09800423T PL 2305653 T3 PL2305653 T3 PL 2305653T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
renal failure
chronic renal
chronic
failure
Prior art date
Application number
PL09800423T
Other languages
English (en)
Inventor
Fuko Matsuda
Katsuhiko Iseki
Hajimu Kurumatani
Mitsuko Miyamoto
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41570369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2305653(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2305653T3 publication Critical patent/PL2305653T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09800423T 2008-07-23 2009-07-23 Środek terapeutyczny stosowany w przewlekłej niewydolności nerek PL2305653T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008190085 2008-07-23
PCT/JP2009/063153 WO2010010909A1 (ja) 2008-07-23 2009-07-23 慢性腎不全処置剤
EP09800423.7A EP2305653B9 (en) 2008-07-23 2009-07-23 Therapeutic agent for chronic renal failure

Publications (1)

Publication Number Publication Date
PL2305653T3 true PL2305653T3 (pl) 2015-08-31

Family

ID=41570369

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09800423T PL2305653T3 (pl) 2008-07-23 2009-07-23 Środek terapeutyczny stosowany w przewlekłej niewydolności nerek

Country Status (12)

Country Link
US (1) US8575175B2 (pl)
EP (1) EP2305653B9 (pl)
JP (1) JP5609643B2 (pl)
KR (1) KR101587071B1 (pl)
CN (1) CN102105453B (pl)
BR (1) BRPI0916282B8 (pl)
CA (1) CA2730599C (pl)
ES (1) ES2532858T3 (pl)
MX (1) MX2011000897A (pl)
MY (1) MY163762A (pl)
PL (1) PL2305653T3 (pl)
WO (1) WO2010010909A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (ja) * 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
PL2663313T3 (pl) * 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
AU2015223908C1 (en) * 2014-02-26 2020-12-03 Nippon Zoki Pharmaceutical Co., Ltd. Progress-Suppressing or Improving Agent for Chronic Kidney Disease
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
TWI746660B (zh) 2016-10-06 2021-11-21 日商第一三共股份有限公司 尿素衍生物及其用途
MX2020007315A (es) 2017-09-28 2020-08-20 Nippon Shinyaku Co Ltd Cristal.
AR113882A1 (es) 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
WO2019117654A1 (ko) 2017-12-15 2019-06-20 (주)녹십자웰빙 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093973A (ja) 1995-06-26 1997-01-07 Kubota Corp 作業機械の走行装置
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JPH1121843A (ja) 1997-07-08 1999-01-26 Nippon Kaiyo Consultant Kk 海水循環方法
JP3181859B2 (ja) 1997-07-08 2001-07-03 三菱電機株式会社 電力変換装置
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
JP2000067748A (ja) 1998-08-26 2000-03-03 Matsushita Electronics Industry Corp カラー陰極線管の製造方法
US6335459B1 (en) * 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
US20030036513A1 (en) 1999-02-16 2003-02-20 Yurkow Edward J. Method for treating cancer
EP1106176B1 (en) 1999-05-10 2008-06-18 Toray Industries, Inc. Remedies for renal failure
JP3858521B2 (ja) 1999-06-28 2006-12-13 松下電器産業株式会社 移動体識別装置
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
DK1178047T3 (da) 2000-08-03 2004-05-24 Pfizer Prod Inc Diazabicyclooctanderivater og terapeutiske anvendelser deraf
TWI316055B (pl) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US7104566B2 (en) 2002-04-25 2006-09-12 Delphi Technologies, Inc. Airbag module and cover arrangement
JP4340111B2 (ja) 2003-08-08 2009-10-07 大成化工株式会社 ポンプ容器
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
PL364348A1 (pl) * 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
JP4694900B2 (ja) 2005-06-28 2011-06-08 株式会社ディスコ レーザー加工方法
EP1913946B1 (en) * 2005-07-08 2014-03-05 Toray Industries, Inc. Therapeutic agent and treatment method for ameliorating uremia
EP2246336B1 (en) 2008-02-28 2020-07-01 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
CN102271685A (zh) 2008-12-30 2011-12-07 斯若姆博洛捷克有限公司 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
SG176915A1 (en) * 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals

Also Published As

Publication number Publication date
JP5609643B2 (ja) 2014-10-22
JPWO2010010909A1 (ja) 2012-01-05
EP2305653B9 (en) 2015-06-24
ES2532858T3 (es) 2015-04-01
US8575175B2 (en) 2013-11-05
BRPI0916282B1 (pt) 2019-10-29
WO2010010909A1 (ja) 2010-01-28
MX2011000897A (es) 2011-03-30
CA2730599A1 (en) 2010-01-28
EP2305653A1 (en) 2011-04-06
CA2730599C (en) 2016-09-13
KR20110036572A (ko) 2011-04-07
CN102105453B (zh) 2016-05-25
CN102105453A (zh) 2011-06-22
US20110178103A1 (en) 2011-07-21
KR101587071B1 (ko) 2016-01-20
MY163762A (en) 2017-10-31
BRPI0916282B8 (pt) 2021-05-25
HK1159104A1 (zh) 2012-07-27
EP2305653A4 (en) 2012-05-16
EP2305653B1 (en) 2015-03-04
ES2532858T9 (es) 2015-07-03

Similar Documents

Publication Publication Date Title
PL2258395T3 (pl) Środek terapeutyczny na zwłóknienie płuca
EP2122343A4 (en) MONITOR RENAL
ZA201005065B (en) Multilayer scaffold
IL211293A0 (en) Combination therapy for tuberculosis
GB0815696D0 (en) Dual model approach for boiler section cleanlines calculation
EP2238063A4 (en) SECURING SYSTEM FOR LIFT
PT2144966E (pt) Estrutura em multicamada
PT2250280E (pt) Utilizações terapêuticas da gelsolina na insuficiência renal
GB0813740D0 (en) Therapeutic compounds
IL205053A0 (en) Trans - clomiphene for metabolic syndrome
GB0806794D0 (en) Therapeutic compounds
GB0804755D0 (en) Therapeutic compounds
GB0716532D0 (en) Therapeutic compounds
GB0813087D0 (en) Therapeutic compounds
AP3125A (en) Failure mechanism for mechanical connection
ZA201003287B (en) Self-tanning effects
ZA201006996B (en) Firefighting unit
GB0708188D0 (en) Therapeutic compounds
GB0702862D0 (en) Therapeutic compounds
GB0717450D0 (en) Medicament
ZA201003835B (en) Therapeutic agent for ulcer
IL218495A0 (en) Theraputic agent for chronic pain
GB0708186D0 (en) Therapeutic compounds
GB0802767D0 (en) Multilayer scaffold
GB0801405D0 (en) Multilayer scaffold